27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Our findings show that the first months of the outbreak did not significantly impact the cognition, quality of life, perceived health status, and depression of our study population when making comparisons with baseline assessments prior to the outbreak. 5 key findings →
Design: cohort study Participants: 75 Evidence: high
Full summary, score breakdown and related studies → Original source
The present study will address several shortcomings of previous CCT studies. 5 key findings →
Design: randomized controlled trial Participants: 162 Evidence: high
Full summary, score breakdown and related studies → Original source
Well-designed and executed RCTs are needed to confirm our findings on stroke and to have more scientific evidence available for the other neurological diseases. 4 key findings →
Participants: 2,335 Evidence: high
Full summary, score breakdown and related studies → Original source
The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to validate biomarkers for Alzheimer's disease (AD) clinical trials. 1 key finding →
Design: longitudinal study Participants: 20,000 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The rapidly increasing worldwide population of older adults, along with the increasing prevalence of cognitive impairment and dementia in this population, is a growing health-care problem. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Common genetic variance in apolipoprotein E (APOE), β-glucocerebrosidase (GBA), microtubule-associated protein tau (MAPT), and α-synuclein (SNCA) has been linked to cognitive decline in Parkinson's disease (PD), although studies have yielded mixed results. 4 key findings →
Design: longitudinal study Participants: 281 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
To the best of our knowledge, this will be the first systematic review and meta-analysis of narrowly defined CCT across clinical populations with depression. 3 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Longitudinal cognitive testing is essential for developing novel preventive interventions for dementia and Alzheimer's disease; however, the few available tools have significant practice effect and depend on an external evaluator. 4 key findings →
Design: longitudinal study Participants: 50 Evidence: moderate
Full summary, score breakdown and related studies → Original source
DNS-br total score and majority of the 11 DNS-br neurocognitive subdomain scores were significantly associated with FDG-PET resilience signature, PIB ratio, cerebral gray matter and white matter volume after adjusting for multiple testing. 5 key findings →
Design: cohort study Participants: 283 Evidence: moderate
Full summary, score breakdown and related studies → Original source
There are 9.9 million new cases of dementia in the world every year. 4 key findings →
Design: randomized controlled trial Participants: 52 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Atrial fibrillation (AF) is the most common clinical arrhythmia with substantial health and socioeconomic impact on healthcare.1 The number of people affected by this condition was estimated to be 33.5 million in 2010, with an increasing prevalence and incidence over the coming years.2 In 2017, there were 37.6 million [95% confidence interval (CI): 32.5–42.6 million] individuals with AF/atrial flutter globally.3 The estimated number of subjects with AF in 2030 in Europe will be 14–17 million, and the number of new cases of AF per year at 120 000–215 000.4 Atrial fibrillation is independently associated with increased mortality and morbidity from complications such as ischaemic stroke, dementia, and cognitive dysfunction.5 Oral anticoagulation can significantly reduce the risk of stroke, dementia, and death.6 As a part of a holistic or integrated approach to AF care, it is associated with improved outcomes7–9 and is advocated in guidelines.10,11 In many patients, AF can be asymptomatic, and the diagnosis is established after the appearance of a complication typically associated with AF, such as ischaemic stroke/systemic embolic or heart failure. 5 key findings →
Participants: 280 Evidence: high
Full summary, score breakdown and related studies → Original source
Overall, individuals improved on all C3 measures over 12 months (β = 0.23, 95% CI [0.21-0.25], p < 0.001), but improvement over the first 3 months was greatest (β = 0.68, 95% CI [0.59-0.77], p < 0.001), suggesting stronger PE over initial repeated exposures. 4 key findings →
Participants: 114 Evidence: low
Full summary, score breakdown and related studies → Original source
Biomarkers for the early detection of dementia risk hold promise for better disease monitoring and targeted interventions. 4 key findings →
Participants: 1,140 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Baseline data predicted that 36 patients with MCI would progress to the AD clinical syndrome (ADS Progressing). 4 key findings →
Participants: 107 Evidence: low
Full summary, score breakdown and related studies → Original source
The SLS is a valid and reliable self-administered memory test that shows promise for remote assessment of aging and neurodegenerative disorders. 1 key finding →
Participants: 96 Evidence: low
Full summary, score breakdown and related studies → Original source
The pattern of deficits across tasks was qualitatively compared with normal age-related decline, and early-stage dementia. 3 key findings →
Participants: 460 Evidence: low
Full summary, score breakdown and related studies → Original source
Differences in expressing facial emotions are broadly observed in people with cognitive impairment. 3 key findings →
Participants: 493 Evidence: low
Full summary, score breakdown and related studies → Original source
Overall, the results suggest that ARC is reliable and valid and represents a feasible tool for assessing cognitive changes associated with the earliest stages of AD. 4 key findings →
Participants: 22 Evidence: low
Full summary, score breakdown and related studies → Original source
We found patient and care partner input to be critical throughout the development process for early identification of design and usability issues and for identifying solutions not previously considered by our research team. 2 key findings →
Participants: 13 Evidence: low
Full summary, score breakdown and related studies → Original source
BrainCheck was able to distinguish between diagnoses of dementia, MCI, and NC, providing a potentially reliable tool for early detection of cognitive impairment. 1 key finding →
Participants: 99 Evidence: low
Full summary, score breakdown and related studies → Original source
Our results suggest that the ki:e SB-C is an objective, scalable, and reliable indicator of cognitive decline, fit for purpose as a remote assessment in clinical early dementia trials. 3 key findings →
Participants: 69 Evidence: low
Full summary, score breakdown and related studies → Original source
MDT-OS and ORR-LDR were weakly-to-moderately correlated with the Preclinical Alzheimer's Cognitive Composite (PACC5) (r = 0.3-0.44, p < .001) and with several other measures of episodic memory, processing speed, and executive function. 5 key findings →
Participants: 172 Evidence: low
Full summary, score breakdown and related studies → Original source
This is the first study to investigate the effect of MAKSCog, an individualised CCT, specifically developed for people with different subtypes of MCI. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
A total of 103 participants completed all investigations and were included in the analysis. 5 key findings →
Participants: 103 Evidence: low
Full summary, score breakdown and related studies → Original source
Reduced speed and reduced smoothness in speed and pressure were observed particularly in the LBD group, while increased pauses and total durations were observed in both the AD and LBD groups. 3 key findings →
Participants: 47 Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →